NeoStem (NYSE MKT: NBS) Divestiture of Ownership Interest in Suzhou Erye closes
November 13th, 2012
No comments
Adds $12.3 M in Non-Dilutive Cash to and Removes Over $30 M of Debt from its Balance Sheet … Read more…
Archive
Archive for the ‘NeoStem’ Category
NeoStem (NYSE MKT: NBS) Effect of Timing of Cell Therapy Following Heart Attack
November 7th, 2012
No comments
New published data is consistent with Amorcyte’s trial results … Read more…
Categories: NeoStem, NeoStem (NYSE MKT: NBS)
NeoStem’s (Amex: NBS), Amorcyte awarded Patent
January 10th, 2012
No comments
Amorcyte’s, a NeoStem company (NYSE Amex: NBS) patent award Read more…
Categories: NBS’s Progenitor Cell Therapy (PCT), NeoStem, New Patent
NeoStem’s (AMEX: NBS) Progenitor Cell Therapy announce a Manufacturing Agreement
October 3rd, 2011
No comments
ImmunoCellular Therapeutics (OTC BB: IMUC) has added NBS’s subsidiary, Progenitor Cell Therapy (PCT) as a 2nd manufacturing site Read more…
Categories: AMEX: NBS, NBS’s Progenitor Cell Therapy (PCT), NeoStem
NeoStem (AMEX: NBS) change in Presentation Time for JMP Securities Conference
September 27th, 2011
No comments
NYSE Amex: NBS changed its previously announced presentation at the 6th Annual JMP Securities Healthcare Conference. Read more…
NeoStem (AMEX: NBS) Receipt of $1.78M in DOD Funding for its VSEL™ Technology to Treat Osteoporosis
August 8th, 2011
No comments
The award is being made Read more…
Categories: AMEX: NBS, DOD Award to treat Osteoporosis, NeoStem
NeoStem (AMEX: NBS) Updating Facts, Economics, Assets and Potential
July 21st, 2011
No comments
NeoStem announced, 7/14/11, the acquisition of Amorcyte; AMR-001, with a P2 study for the treatment of acute myocardial infarction (AMI). Read more…
Breaking NEWS: NeoStem (AMEX: NBS) signs Definitive Merger Agreement to acquire Amorcyte in Equity Transaction
July 14th, 2011
No comments
Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease. Read more…
Categories: AMEX: NBS, Definitive Merger Agreement, NeoStem
NeoStem (AMEX: NBS) Partners with Vatican’s Pontifical Council to advance Adult Stem Cell Research
June 16th, 2011
No comments
Cardinal Gianfranco Ravasi, President of the Pontifical Council for Culture, Dr. Robin L. Smith, Chairman/CEO of NBS, and Reverend Tomasz Trafny, Head of the Science and Faith Department at the Pontifical Council for Culture provided details Read more…
Categories: AMEX: NBS, NeoStem, Partners with Vatican’s Pontifical Council
$19M Concurrent Offerings, NeoStem (Amex: NBS)
November 16th, 2010
No comments
NBS announced concurrently a 6.337M common stock offering with a warrant at $1.45 and a registered direct offering of 10,582,011 preferred units. Read more…
Categories: AMEX: NBS, financings, NeoStem, Registered Direct Offering, Stem Cell Technology
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.